The nurse is administering IV fluconazole to a client who has systemic candidiasis. After reviewing the client's diagnostic studies, the nurse identifies a rising trend in the liver enzyme levels for aspartate aminotransferase (AST). Which action should the nurse implement?

A. Begin the infusion and submit a drug reaction report to the nursing supervisor: Starting the infusion despite evidence of rising AST could worsen hepatic injury, as fluconazole is metabolized in the liver and may cause hepatotoxicity. B. Hold the dose and notify the healthcare provider (HCP) of the changes in the laboratory studies: Rising AST indicates possible liver damage, and administering more fluconazole could exacerbate the injury. This action allows for further evaluation, potential discontinuation, or dosage adjustment to prevent progression of hepatic toxicity. C. Hold the dose and notify the pharmacy to stop dispensing the next premixed doses: While preventing further dispensing can help avoid repeated administration, it is not the nurse’s primary responsibility in urgent patient care. The priority is to alert the HCP immediately. D. Begin the infusion and monitor the client's blood urea nitrogen (BUN), serum creatinine, and liver function tests: Continuing the infusion despite worsening liver enzymes puts the client at risk for serious hepatic injury.